The use of infliximab in South-east Asian children with severe Crohn's disease
Childhood Crohn's disease (CD) has a chronic relapsing course with a high morbidity which includes delayed puberty, impaired growth, and perianal disease1. It is most prevalent in North America, North-west Europe, and in the United Kingdom, and is rare in Asia1. Many children with CD eventually...
| Main Author: | |
|---|---|
| Format: | Article |
| Published: |
2004
|
| Subjects: |
| _version_ | 1825719934327455744 |
|---|---|
| author | Lee, W.S. |
| author_facet | Lee, W.S. |
| author_sort | Lee, W.S. |
| collection | UM |
| description | Childhood Crohn's disease (CD) has a chronic relapsing course with a high morbidity which includes delayed puberty, impaired growth, and perianal disease1. It is most prevalent in North America, North-west Europe, and in the United Kingdom, and is rare in Asia1. Many children with CD eventually need corticosteroid to control symptoms1. Tumor necrosis factor α (TNFα) is a proinflammatory cytokine which is important in the pathogenesis of CD2. Infliximab (Remicade, Schering-Plough, Kenilworth, New Jersey, USA), a chimeric anti-TNFα monoclonal antibody, induces remission in patients with moderately to severely active CD and can reduce corticosteroid requirements3. We share our experience in the use of infliximab in three South-east Asian children with severe CD. |
| first_indexed | 2024-03-06T05:27:19Z |
| format | Article |
| id | um.eprints-10915 |
| institution | Universiti Malaya |
| last_indexed | 2024-03-06T05:27:19Z |
| publishDate | 2004 |
| record_format | dspace |
| spelling | um.eprints-109152014-07-10T01:03:08Z http://eprints.um.edu.my/10915/ The use of infliximab in South-east Asian children with severe Crohn's disease Lee, W.S. R Medicine RJ Pediatrics Childhood Crohn's disease (CD) has a chronic relapsing course with a high morbidity which includes delayed puberty, impaired growth, and perianal disease1. It is most prevalent in North America, North-west Europe, and in the United Kingdom, and is rare in Asia1. Many children with CD eventually need corticosteroid to control symptoms1. Tumor necrosis factor α (TNFα) is a proinflammatory cytokine which is important in the pathogenesis of CD2. Infliximab (Remicade, Schering-Plough, Kenilworth, New Jersey, USA), a chimeric anti-TNFα monoclonal antibody, induces remission in patients with moderately to severely active CD and can reduce corticosteroid requirements3. We share our experience in the use of infliximab in three South-east Asian children with severe CD. 2004 Article PeerReviewed Lee, W.S. (2004) The use of infliximab in South-east Asian children with severe Crohn's disease. Pediatrics International, 46 (2). pp. 198-201. ISSN 1328-8067, DOI https://doi.org/10.1046/j.1442-200x.2004.01870.x <https://doi.org/10.1046/j.1442-200x.2004.01870.x>. http://onlinelibrary.wiley.com/store/10.1046/j.1442-200x.2004.01870.x/asset/j.1442-200x.2004.01870.x.pdf?v=1&t=hwrgsixt&s=868de4249563a591b68c9c9d39fdd5e3596cdc3d 10.1046/j.1442-200x.2004.01870.x |
| spellingShingle | R Medicine RJ Pediatrics Lee, W.S. The use of infliximab in South-east Asian children with severe Crohn's disease |
| title | The use of infliximab in South-east Asian children with severe Crohn's disease |
| title_full | The use of infliximab in South-east Asian children with severe Crohn's disease |
| title_fullStr | The use of infliximab in South-east Asian children with severe Crohn's disease |
| title_full_unstemmed | The use of infliximab in South-east Asian children with severe Crohn's disease |
| title_short | The use of infliximab in South-east Asian children with severe Crohn's disease |
| title_sort | use of infliximab in south east asian children with severe crohn s disease |
| topic | R Medicine RJ Pediatrics |
| work_keys_str_mv | AT leews theuseofinfliximabinsoutheastasianchildrenwithseverecrohnsdisease AT leews useofinfliximabinsoutheastasianchildrenwithseverecrohnsdisease |